Estrella Immunopharma, Inc. - Common Stock (NQ:ESLA)

0.8742 -0.0581 (-6.23%)

Delayed Quote Updated: 12:26 PM EDT, Oct 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors

October 26, 2026

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase

October 15, 2026

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

October 14, 2026

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

August 11, 2026

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

August 03, 2026

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

July 29, 2026

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma

July 24, 2026

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma to Participate in the D. Boral Capital Global Conference

May 05, 2026

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research

March 23, 2026

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

February 09, 2026

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

February 03, 2026

From Estrella Immunopharma, Inc.

Via Business Wire

BioMedNewsBreaks – Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) Closes $8.0 Million Registered Direct Offering

January 07, 2026

Via Investor Brand Network

Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement

January 06, 2026

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

January 05, 2026

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

December 04, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

November 03, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

October 06, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

June 05, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

June 03, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas

May 29, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

March 05, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

February 21, 2025

From Estrella Immunopharma

Via Business Wire

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

February 19, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

September 27, 2024

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

August 14, 2024

From Estrella Immunopharma, Inc.

Via Business Wire

BioMedNewsBreaks – Estrella Immunopharma Inc. (NASDAQ: ESLA, ESLAW) Starts Trading After TradeUP Acquisition Corp., Estrella Biopharma Inc. Business Combination

October 04, 2023

Via Investor Brand Network

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.